
Pharma Weekly Updates in a Quick, 2-Minute Read.
| Platform | Pricing | Only free issues | Publishes | Weekly | |
|---|---|---|---|---|---|
| Issues | 172 | Founded | 3 years ago | Last Issue | 8 days ago |
| Active | |||||

🧬 Google DeepMind released an AlphaGenome-powered atlas predicting the impact of all ~9B possible human DNA mutations, giving researchers a free tool to prioritize potentially pathogenic variants.
🎗️ Moderna and Merck will present full P...
❌ Novartis’ del-desiran failed Phase 3 in DM1, following pelacarsen’s cardiovascular failure and the rap-cel CAR-T halt after 3 deaths, intensifying scrutiny of its pipeline and $12B Avidity acquisition.
⚖️ Novo Nordisk’s Wegovy produc...
🤝 Eli Lilly and Company will acquire Merida Biosciences for up to $2.88B, gaining a platform that selectively degrades pathogenic autoantibodies in autoimmune and allergic diseases.
⚠️ Novartis paused 8 autoimmune and neurological CA...
🎗️ FDA approved Revolution Medicines’ Rasonque for previously treated pancreatic cancer in just 1 month, nearly doubling median survival versus chemotherapy by targeting KRAS-driven disease.
⚖️ Genentech licensed Hanmi Pharmaceuticals’s n...
🎗️ Moderna’s personalized mRNA cancer therapy intismeran plus Keytruda, significantly reduced melanoma recurrence and distant metastasis in Phase 3, the 1st pivotal success for an individualized mRNA cancer treatment.
💔 Sanofi will cut 2...
Subscribers, engagement, traffic and sponsorship for \ud83d\udd2c Latest Pharma Industry Updates.
| Subscribers | Engagement | 70 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
How this newsletter ranks in the official Substack charts.
| #242 |
The writers behind this newsletter.
Pharma Senior Market Analyst providing weekly updates about the Life science industry.
You can find recent issues that have been published by this newsletter on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to this newsletter, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch this newsletter as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact this newsletter using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like this newsletter. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.